Hypertension and osteoporosis Circulatory System Hypertension
Conditions
Interventions
Patients will be randomised to receive one of three treatments:
1. Placebo
2. Potassium citrate
3. Potassium chloride
Sponsors
King's College London (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: To take part in the study, participants will be aged between 22 and 65 years and will have a body mass index (BMI) between 19 and 35 kg/m^2 and alcohol consumption of no more than 21 units (women) or 28 units (men) per week. Volunteers eligible for the study will have the average self-measured systolic blood pressure <160 and average self-measured diastolic blood pressure <105 mmHg (an average of 20 readings for both systolic and diastolic blood pressure). Those with blood pressure levels higher than these values will be advised to contact their general practitioners. Subjects taking medications for which potassium supplementation is not contraindicated, or mineral and vitamin supplements, will be allowed to participate in the study with the provision that they will not discontinue to use these products.
Exclusion criteria
Exclusion criteria: The main exclusion criteria will be diseases or conditions that might involve collateral effects from potassium supplementation or interfere with its metabolism. These will be insulin dependent diabetes mellitus, non-insulin dependent diabetes mellitus, diabetes insipidus, cardiovascular diseases (including events of cardiac arrhythmia and peripheral arterial disease) or previous cardiovascular events, any kind of renal diseases, metabolic acidosis, current peptic ulcers, dysphagia, general digestive problems, gastric surgery, pregnancy and lactation. Women planning to become pregnant will also be excluded. Other exclusion criteria will be the use of antihypertensive drugs, changes in lifestyle (e.g. dieting, start of new medication), the use of drugs known to interfere with potassium metabolism (cyclosporin, heparin, digoxin, anticholinergics) and prolonged use of non-steroidal anti-inflammatory drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Mean change in systolic and diastolic blood pressure after 6 weeks of treatment 2. Mean change in biomarkers of bone resorption and bone formation 3. Mean change in erythrocyte and plasma electrolytes concentrations | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean change in mean arterial pressure | — |
Countries
United Kingdom
Outcome results
None listed